Synonyms: CTP-543 | CTP543 | D8-ruxolitinib
Compound class:
Synthetic organic
Comment: Deuruxolitinib (CTP-543) is a deuterium-modified analogue of the JAK inhibitor ruxolitinib. It is an oral inhibitor that inhibits JAK1/2. The chemical structure, and its use in hair loss disorders are claimed in patent WO2017192905A1 [2].
|
|
No information available. |
Summary of Clinical Use |
CTP-543 is being progressed through clinical development by Concert Pharmaceuticals, as a treatment for alopecia areata [1]. The FDA has granted Breakthrough Therapy and Fast Track designations for CTP-543. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04518995 | A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | Phase 3 Interventional | Concert Pharmaceuticals | ||
NCT03137381 | Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | Phase 2 Interventional | Concert Pharmaceuticals |